A5044681937- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Mycobacterium research and diagnosis
- Infectious Diseases and Mycology
- Extracellular vesicles in disease
- Tuberculosis Research and Epidemiology
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Cancer Immunotherapy and Biomarkers
- Sarcoidosis and Beryllium Toxicity Research
- Lung Cancer Treatments and Mutations
- Pleural and Pulmonary Diseases
- Actinomycetales infections and treatment
- Lung Cancer Research Studies
- Cystic Fibrosis Research Advances
- Immune Cell Function and Interaction
- Myasthenia Gravis and Thymoma
- Inhalation and Respiratory Drug Delivery
- Cancer-related molecular mechanisms research
- Immunotherapy and Immune Responses
- Respiratory Support and Mechanisms
- IL-33, ST2, and ILC Pathways
- Immune cells in cancer
- Cardiovascular and exercise physiology
- Pituitary Gland Disorders and Treatments
- Monoclonal and Polyclonal Antibodies Research
- Esophageal and GI Pathology
Osaka University
2016-2025
Osaka International University
2020-2024
Toneyama National Hospital
2019-2024
National Hospital Organization
2019-2024
Takeda (United States)
2022
Weatherford College
2022
Nishinomiya Municipal Central Hospital
2012
Abstract The aim of this study was to investigate the clinical impact sarcopenia on efficacy programmed death (PD)-1 inhibitors. We retrospectively reviewed medical records all patients treated with nivolumab or pembrolizumab between January 2016 and September 2018 for previously advanced non–small cell lung cancer (NSCLC). cross-sectional area psoas muscle at level third lumbar vertebra baseline computed tomography assessed calculate index (PMI). Sarcopenia defined based PMI cut-off values...
Immune checkpoint inhibitors (ICIs) have caused revolutionary changes in cancer treatment, but low response rates remain a challenge. Semaphorin 4A (Sema4A) modulates the immune system through multiple mechanisms mice, although role of human Sema4A tumor microenvironment remains unclear. This study demonstrates that histologically Sema4A-positive non–small cell lung (NSCLC) responded significantly better to anti–programmed death 1 (PD-1) antibody than Sema4A-negative NSCLC. Intriguingly,...
BackgroundNovel biomarkers (BMs) are urgently needed for bronchial asthma (BA) with various phenotypes and endotypes.ObjectiveWe sought to identify novel BMs reflecting tissue pathology from serum extracellular vesicles (EVs).MethodsWe performed data-independent acquisition of EVs 4 healthy controls, noneosinophilic (NEA) patients, eosinophilic (EA) patients BA. We confirmed EA-specific via validation in 61 BA 23 controls. To further validate these findings, we 6 chronic rhinosinusitis...
Abstract Background The impact of SARS-CoV-2 infection on the gut fungal (mycobiota) and bacterial (microbiota) communities has been elucidated individually. This study analyzed both mycobiota microbiota their correlation in COVID-19 patients with severe mild conditions follow-up to monitor alterations after recovery. Methods We by 16S ITS1 metagenomic sequencing 40 patients, 38 30 healthy individuals reanalyzed those 10 approximately 6 months discharge. Results groups showed lower diversity...
Significance The therapeutic activity of checkpoint blockers and toll-like receptor (TLR) agonists, which show some efficacy against malignancies, appears to at least partially result from the secretion type-I IFNs. Thus, we hypothesized that IFN-inducible transcription factors, such as basic leucine zipper factor ATF-like 2 ( Batf2 ), might play a role in tumor immunity. Here, investigated , especially its positive transcriptional activities, evaluated antitumor effect. This study shows has...
Limited infiltration and activity of natural killer (NK) T cells within the tumor microenvironment (TME) correlate with poor immunotherapy responses. Here, we examined role endonuclease Regnase-1 on NK cell anti-tumor activity. cell-specific deletion (Reg1ΔNK) augmented cytolytic interferon-gamma (IFN-γ) production in vitro increased intra-tumoral accumulation Reg1ΔNK-NK vivo, reducing growth dependent IFN-γ. Transcriptional changes included elevated IFN-γ expression, effectors, chemokine...
Progressive pulmonary fibrosis (PPF), defined as the worsening of various interstitial lung diseases (ILDs), currently lacks useful biomarkers. To identify novel biomarkers for early detection patients at risk PPF, we performed a proteomic analysis serum extracellular vesicles (EVs). Notably, identified candidate were enriched lung-derived proteins participating in fibrosis-related pathways. Among them, surfactant-associated protein B (SFTPB) EVs could predict ILD progression better than...
We identified 2 novel species, Mycobacterium novusgordonae and M. shingordonae, from sputum specimens of pulmonary disease patients in Japan. Genetic biochemical analyses revealed a close relationship with paragordonae. One shingordonae case-patient experienced severe progressive infection, highlighting the variation pathogenicity gordonae clade species.
Abstract Background Interstitial lung disease (ILD), represented by idiopathic pulmonary fibrosis (IPF) and progressive (PPF), shows poor prognosis due to fibrosis. Early therapeutic intervention is required enhance the efficacy of antifibrotic drugs, highlighting importance early detection ILD progression. Although candidate biomarkers for predicting progression have been recently reported through omics analyses, clinically measurable remain unestablished. This study aimed identify that...
Background: Multidrug therapy is essential for preventing respiratory failure in patients with highly progressive Mycobacterium avium complex pulmonary disease (MAC-PD). However, the prognosis and long-term outcome following combination poorly understood. Methods: We retrospectively evaluated clinical characteristics outcomes chemo-naïve MAC-PD, hospitalized first-line multidrug therapy. Results: Among 125 patients, 86 (68.8%) received standardized treatment (rifampicin, ethambutol,...
Abstract The combination of rifamycin (RFP), ethambutol (EB), and macrolides is currently the standard regimen for treatment Mycobacterium avium complex pulmonary disease (MAC-PD). However, poor adherence to standardized regimens recommended by current guidelines have been reported. We undertook a single-centred retrospective cohort study evaluate long-term outcomes in 295 patients with MAC-PD following first line (RFP, EB, clarithromycin [CAM]) or alternative (EB CAM without...
There is an unmet need for novel biomarkers in the diagnosis of multifactorial COPD. We applied next-generation proteomics to serum extracellular vesicles (EVs) discover COPD biomarkers. EVs from 10 patients with and six healthy controls were analysed by tandem mass tag-based non-targeted proteomics, those elastase-treated mouse models emphysema also proteomics. For validation, 23 20 validated targeted Using we identified 406 proteins, 34 which significantly upregulated Of note, EV protein...
Abstract Coronavirus disease 2019 (COVID‐19) can cause severe lymphopenia and respiratory failure requiring prolonged invasive mechanical ventilation (MV). COVID‐19 patients with or are at risk of developing secondary infections. Here, we present the needle autopsy findings a critically ill patient who required reintubation MV, eventually died cytomegalovirus (CMV) pneumonia. This case highlights potential long‐term steroid use need for routine monitoring CMV infection in COVID‐19.
Abstract Cancer immunotherapy has shown great promise as a new standard therapeutic strategy against cancer. However, the response rate and survival benefit remain unsatisfactory because most current approaches, such use of immune checkpoint inhibitors, depend on spontaneous antitumor responses. One possibility for improving efficacy is to promote immunity using adjuvants or specific cytokines actively. IL-33 been candidate cytokine therapies, but it remains unclear how in which situations...
This is the first report of COVID-19 in a human T-cell lymphotropic virus type-1 (HTLV-1) carrier. HTLV-1 infection can cause immune dysfunction even asymptomatic carriers. case highlights need for guidance on management COVID-19-HTLV-1 coinfection, specifically appropriate use corticosteroid treatment while considering secondary infection.
Abstract Sarcoidosis is a complex, polygenic, inflammatory granulomatous multi-organ disease of unknown cause. The inflammation in sarcoidosis driven by the interplay between T cells and macrophages. Extracellular vesicles (EVs) play important roles intercellular communication. We subjected serum EVs, isolated size exclusion chromatography, from seven patients with five control subjects to non-targeted proteomics analysis. Non-targeted, label-free analysis detected 2292 proteins EVs; 42 were...
ABSTRACT This single-center retrospective study aimed to analyze the variability of macrolide resistance (MR) in 68 patients with Mycobacterium avium complex pulmonary disease. Among 25 treated without macrolides, 13 (52%) reverted macrolide-susceptible (MS) profiles. Only one (2%) 43 who continued treatment showed this change. We compared 30 MR isolates recent specimens. them, seven shifted MS (five attributed clonally related strains; two resulting from reinfection or polyclonal infection).
Abstract Background Lung resection in patients with nontuberculous mycobacterial pulmonary disease (NTM-PD) has been reported to be associated favorable outcomes. However, little is known regarding the risk and prognostic factors for refractory recurrent cases. We aimed evaluate overall impact benefit of adjuvant lung surgery by comparing NTM-PD who underwent those treated exclusively antibiotics. also investigated efficacy serum IgA antibody against glycopeptidolipid (GPL) core antigen (GPL...
Objective No studies have demonstrated the real-world efficacy of antifibrotics for progressive fibrosing interstitial lung disease (PF-ILD). Therefore, we evaluated in patients with PF-ILD. Methods We retrospectively reviewed medical records ILD from January 2012 to July 2021. Patients were diagnosed PF-ILD if they had ≥10% fibrosis on high-resolution CT (HRCT) and a relative forced vital capacity (FVC) decline either or >5% <10% clinical deterioration progression HRCT during...